OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Singh on Combination Therapy in Localized Bladder Cancer

October 22nd 2019

Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.

Dr. Pettaway on Importance of Inclusive Germline Testing in Prostate Cancer

October 22nd 2019

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Dr. Mato on Immunotherapy Options in CLL

October 22nd 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer Treatment

October 22nd 2019

Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.

Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

October 21st 2019

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Dr. Gonzalez-Martin on Rationale for Phase III PRIMA Trial in Advanced Ovarian Cancer

October 21st 2019

Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

October 21st 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Dr. McGregor on Unmet Needs in Non-Clear Cell RCC

October 21st 2019

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

October 21st 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

October 21st 2019

Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Dr. Long on Sequencing Local Therapy in Patients With Melanoma Who Have Brain Mets

October 21st 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the sequence of local therapy in patients with melanoma who have brain metastases.

Dr. Schiller on the Heterogeneity of AML

October 19th 2019

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Dr. Zelenetz on Zanubrutinib Research in MCL

October 18th 2019

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.

Dr. Weber on Toxicity Data From CheckMate-238 Trial in Melanoma

October 18th 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

October 18th 2019

David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.

Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple Myeloma

October 17th 2019

Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.

Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases

October 17th 2019

Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.

Dr. Borghaei on the Clinical Utility of PD-L1 in Advanced NSCLC

October 17th 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses the clinical utility of PD-L1 in advanced non–small cell lung cancer (NSCLC).

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRC

October 17th 2019

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.